Eyepoint, Inc. (EYPT) — SEC Filings
Eyepoint, Inc. (EYPT) — 50 SEC filings. Latest: 8-K (May 6, 2026). Includes 27 8-K, 6 10-Q, 6 SC 13G/A.
View Eyepoint, Inc. on SEC EDGAR
Overview
Eyepoint, Inc. (EYPT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: EyePoint Pharmaceuticals, Inc. filed an 8-K on December 8, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as pSivida Corp. and pSivida LTD, is incorporated in Delaware and headquartered in Watertown, Massachusetts.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 47 neutral. The dominant filing sentiment for Eyepoint, Inc. is neutral.
Filing Type Overview
Eyepoint, Inc. (EYPT) has filed 27 8-K, 6 10-Q, 1 8-K/A, 1 DEFA14A, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 5 SC 13G with the SEC between Mar 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of EYPT's 34 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $30.75M |
| Net Income | -$164.35M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $204.0M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Marc O. Classen
- Dr. David E. E. Slosberg
- Jay Duker
- Nancy Lurker
- Dr. Marc O. Spiegel
- Dr. Peter S. Arduini
- Ms. Susan L. Levinson
- Dr. Yiannis Monioudis
- Dr. David R. Guyer
- Dr. Joan W. Miller
- Ms. Jennifer L. Chien
Industry Context
The pharmaceutical industry, particularly in ophthalmology, is characterized by high R&D costs, lengthy development cycles, and significant regulatory oversight. Companies like EyePoint compete in a space with established players and are driven by innovation in treating conditions like wet AMD. Success hinges on demonstrating clinical superiority and navigating complex market access and reimbursement landscapes.
Top Tags
financials (7) · 8-K (6) · financial-reporting (6) · filing (4) · corporate-actions (4) · 10-Q (4) · pharmaceuticals (3) · EyePoint Pharmaceuticals (3) · corporate-filing (2) · amendment (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 000-51122 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 26-2774444 | Company's tax identification number. |
| Net Loss | $164.35M | Increased from $89.47M in 2024 for nine months ended Sep 30, 2025 |
| Research and Development Expenses | $161.83M | Increased from $89.55M in 2024 for nine months ended Sep 30, 2025 |
| Total Revenues | $30.75M | Decreased from $31.69M in 2024 for nine months ended Sep 30, 2025 |
| Cash, Cash Equivalents and Marketable Securities | $204.0M | As of September 30, 2025 |
| Net Proceeds from Equity Financing | $162.1M | Received in October 2025 |
| Common Stock Shares Outstanding | 82,787,220 | As of October 30, 2025 |
| Net Loss (Q3 2025) | $59.73M | Increased from $29.36M in Q3 2024 |
| R&D Expenses (Q3 2025) | $47.75M | Increased from $29.54M in Q3 2024 |
| Royalty Income | $12.92M | Increased from $1.39M in 2024 for nine months ended Sep 30, 2025 |
| License and Collaboration Agreements Revenue | $16.53M | Decreased from $27.91M in 2024 for nine months ended Sep 30, 2025 |
| Product Sales Revenue | $1.1M | for Q2 2025, decreased from $1.3M in Q2 2024 |
| Research and Development Expense | $22.6M | for Q2 2025, increased from $17.6M in Q2 2024 |
| General and Administrative Expense | $10.1M | for Q2 2025, increased from $9.7M in Q2 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Eyepoint, Inc. (EYPT)?
Eyepoint, Inc. has 50 recent SEC filings from Mar 2024 to May 2026, including 27 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EYPT filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 47 neutral. The dominant sentiment is neutral.
Where can I find Eyepoint, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Eyepoint, Inc. (EYPT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Eyepoint, Inc.?
Key financial highlights from Eyepoint, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EYPT?
The investment thesis for EYPT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Eyepoint, Inc.?
Key executives identified across Eyepoint, Inc.'s filings include Dr. Marc O. Classen, Dr. David E. E. Slosberg, Jay Duker, Nancy Lurker, Dr. Marc O. Spiegel and 6 others.
What are the main risk factors for Eyepoint, Inc. stock?
Of EYPT's 34 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Eyepoint, Inc.?
Forward guidance and predictions for Eyepoint, Inc. are extracted from SEC filings as they are enriched.